Page 26 - Mployee Wellness Programs News Today

Dyne Therapeutics recently reported encouraging Phase 1/2 clinical data in myotonic dystrophy type 1 and Duchenne muscular dystrophy. At the J.P. Morgan Healthcare Conference, CEO Joshua Brumm said Dyne’s existing cash combined with the new capital is expected to last through 2025—well beyond the next key milestones for both therapeutic candidates.

Kevin Sayer would love to bring his company's Dexcom G7 continuous glucose monitor to more people and more quickly. But despite being CEO of a successful device company, he feels frustrated from time to time about how and what the U.S. health system will pay for.

In this episode, we’re joined by Dr. Bruce Dorr, an OB-GYN. Dorr discusses how the lack of medical training for menopause has led to insufficient treatment.

The FDA has found no clear relationship between GLP-1 drugs, such as Ozempic and Mounjaro, and reports of suicidal thoughts or actions. But the agency added that it can’t definitively rule out the risk, and its review is ongoing.

Generic competition has eroded sales of multiple sclerosis drug Ampyra, marketed as Fampyra outside the U.S. Biogen told Acorda Therapeutics that it’s terminating its ex-U.S. rights to Fampyra in order to focus on other priorities, which include expanding beyond MS.

At CES 2024, menopause startup Amira launched The Terra System, a wearable cooling device that supports women battling hot flashes and helps them sleep through the night.

This year's J.P. Morgan Healthcare Conference brought a bevy of news announcements — from acquisitions to partnerships to new products and more. This list compiles short summaries for seven of the event’s most notable announcements.

New research found that there are no racial disparities in weight loss results among patients taking obesity drugs. However, the study found that people of color have less access to services like behavioral care or surgical interventions, which are often needed in order for obese patients to lose weight and keep it off. To tackle this issue, Enara Health CEO Rami Bailony argued that the U.S. healthcare system must innovate the way it dispenses weight loss drugs, employing a more holistic care ap...

U.S. healthcare is unnecessarily spending millions of dollars on scopes—dollars that could be better spent opening up new service lines, investing in medical equipment, or hiring nurses for improved patient care.

The innovator’s mindset is shifting from solving the problems right in front of us to solving problems once considered impossible to fix. The lines between curable and incurable diseases are blurring in surgery because medical devices are scaling up precision and scaling down the size of anatomy that surgeons can operate on.